HLA-A3 Antigen

"HLA-A3 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*03 allele family.

Descriptor ID

D015791

MeSH Number(s)

D12.776.395.550.489.400.030

D12.776.543.550.421.400.030

D23.050.301.500.100.400.030

D23.050.301.500.450.370.030

D23.050.705.552.100.400.030

D23.050.705.552.450.370.376

Concept/Terms

HLA-A3 Antigen

HLA Class I Histocompatibility Antigen, A-3 alpha Chain

Below are MeSH descriptors whose meaning is more general than "HLA-A3 Antigen".

Chemicals and Drugs [D]
Biological Factors [D23]
Antigens [D23.050]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
HLA Antigens [D23.050.705.552.450]
HLA-A Antigens [D23.050.705.552.450.370]
HLA-A3 Antigen [D23.050.705.552.450.370.376]

Below are MeSH descriptors whose meaning is related to "HLA-A3 Antigen".

Below are MeSH descriptors whose meaning is more specific than "HLA-A3 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HLA-A3 Antigen" by people in Harvard Catalyst Profiles by year, and whether "HLA-A3 Antigen" was a major or minor topic of these publication.

Below are the most recent publications written about "HLA-A3 Antigen" by people in Profiles.

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 01; 23(1):172-184.

View in: PubMed
Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.

View in: PubMed
Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 2015 Oct 30; 290(44):26562-75.

View in: PubMed
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014 Sep; 25(9):1735-1742.

View in: PubMed
Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. Hum Vaccin Immunother. 2012 Jul; 8(7):987-1000.

View in: PubMed
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012 May 15; 118(10):2594-602.

View in: PubMed
Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J Clin Invest. 2011 Jun; 121(6):2480-92.

View in: PubMed
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol. 2011 Jan; 12(1):45-53.

View in: PubMed
Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. J Neurovirol. 2010 Feb; 16(1):41-7.

View in: PubMed
Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med. 2010 Jan 18; 207(1):61-75.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

J Immunol
Clin Cancer Res
Proc Natl Acad Sci U S A
Lancet Oncol
J Neuroimmunol
J Immunother
J Biol Chem
Int J Cancer
Int Immunol
Am J Respir Crit Care Med